Contribution to diagnosis and management of reactional states: A practical approach

Anais Brasileiros de Dermatologia

Volumn 81, Issue 4, 2006, Pages 367-375

  Nery, José Augusto Da Costa ^a,b   Sales, Anna Maria ^a   Illarramendi, Ximena ^a   Duppre, Nádia Cristina ^a   Jardim, Márcia Rodrigues ^a   Machado, Alice Miranda ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Escola Nacional de Saúde Pública ^*  (Brazil)

Author keywords

Diagnosis; Erythema nodosum; Leprosy; Neuritis

Indexed keywords

ADENOSINE DEAMINASE; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; BETA 2 MICROGLOBULIN; CLOFAZIMINE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1; METHYLPREDNISOLONE; NEOPTERIN; PENTOXIFYLLINE; PREDNISONE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL FEATURE; CLINICAL PRACTICE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; ERYTHEMA MULTIFORME; ERYTHEMA NODOSUM; ERYTHEMA NODOSUM LEPROSUM; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; LEPROSY; NEURITIS; PATHOPHYSIOLOGY; REVIEW; SINGLE DRUG DOSE; SKIN MANIFESTATION;

EID: 34248652113     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/s0365-05962006000400010     Document Type: Review

References (59)

1. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five group system. Int J Lepr. 1966;34:255-73.
2. Lienhardt C, Fine PEM. Type 1 reaction neuritis and disability in leprosy. What is the current epidemiological situation? Lepr Rev. 1994;65:9-33.
3. Nery JAC, Vieira LMM, Matos HJ, Gallo MEN, Sarno EN. Reactional states in multibacillary disease patients during multidrug therapy. Rev Inst Med Trop São Paulo. 1998;40:363-70.
4. Rose P, Waters MFR. Reversal reactions in leprosy and their management. Lepr Rev. 1991;62:113-21.
5. Naafs B. Leprosy reactions. New Knowledge. Trop Geogr Med. 1994;46:80-4.
6. Nery JAC, Garcia CC, Wanzeller SHO, Sales AM, Gallo MEN, Vieira LMM. Características clínico-histopatológicas dos estados reacionais na Hanseníase em pacientes submetidos à poliquimioterapia (PQT). An Bras Dermatol. 1999;74:1-7.
7. Rea TH. An overview of reactional states in Hansen's. Disease Star. 1989;49:1-6.
8. Oliveira MLW, Gomes MK, Pimentel MIF, Castro MCR. Reação reversa macular pós-alta de poliquimioterapia multibacilar. Hansenol Int. 1996;21:46-51.
9. Nery JAC. Reação na Hanseníase: uma descrição epidemiológica [tese]. Niterói: Universidade Federal Fluminense; 1995. p. 129.
10. Valentini A, Nery JAC, Sales AM, Vieira LMM, Sarno EN. Edema in leprosy: clinical and therapeutic aspects. Rev Soc Bras Med Trop. 1999;32:131-8.
11. Sales AM. Parâmetros séricos de reatividade imunológica na reação reversa [tese]. Rio de Janeiro: Universidade Federal do Rio de Janeiro; 1999. p.109.
12. Sarno EN, Grau GE, Vieira LM, Nery JAC. Serum levels of tumour necrosis factor alpha and interleukin 1 beta during leprosy reactional states. Clin Exp Immunol. 1991;84:103-8.
13. Guerra JG, Penna GO, Castro LCM, Martelli CMT, Stefani MMA. Eritema nodoso hansênico: atualização clínica e terapêutica. An Bras Dermatol. 2002;77:389-410.
14. Lockwood DNJ. The management of erythema nodosun leprosum: current and future options. Lepr Rev. 1996;67:253-9.
15. Vieira LMM, Nery JAC, Duppre NC, Malta AM, Sarno EM. Alguns aspectos clínicos da Reação Tipo 2 em pacientes lepromatosos submetidos a poliquimioterapia. An Bras Dermatol. 1993;68:383-9.
16. Browne SG. Erythema nodosum in leprosy. J Chronic Dis. 1963;16:23-30.
17. Vieira LMM. Erytema nodosum lepromosum: alguns aspectos clínicos e imunológicos [tese]. Rio de Janeiro: Instituto Oswaldo Cruz; 1991. p. 163.
18. Talhari S, Garrido Neves R. Tratamento. In: Dermatologia Tropical - Hanseníase. 3 ed. Manaus: Gráfica Tropical; 1997. p.167.
19. Garcia-Afonso MCZ. Lesões reacionais tipo eritema multiforme na hanseníase [monografia]. Rio de Janeiro: Instituto Carlos Chagas;1999. p.79.
20. Miranda MA, Valentin V, Nery JAC, Sarno EN. Parâmetros clínicos e morfológicos do eritema multiforme na hanseníase. Rev Soc Bras Med Trop. 2000;33(Suppl 1):S101-2.
21. Latapi F, Zamora AC. The "spotted" leprosy of Lucio. An introduction to it's clinical and hitopatological study. Int J Lepr Other Mycobact Dis. 1948;16:421-9.
22. Azulay RD, Azulay DR. Micobacterioses. In: Dermatologia. 2 ed. Rio de Janeiro: Guanabara Koogan; 1997. p.174-89.
23. Ridley DS. Reactions in leprosy. Int J Lepr. 1969;47:77-81.
24. Cochrane RG. Reactions in leprosy. In: Cochrane RG, editor. Leprosy in theory and practice. Toronto: John Wrights & Sons; 1959. p.177-87.
25. Nery JAC, Malta AM, Duppre NC, Gallo MEN, Sarno EN. Letters to the editor. Cor pulmonale acute and recurrent erythema nodosum leprosum. Lepr Rev. 1993;64:21-8.
26. Kuntz JL, Meyer R, Vautravers PH, Kieffer D, Asch L. Polyarthrites au cours de la lèpre. Sem Hop Paris. 1979;55:1889-92.
27. Atkin SL, El-Ghobarey A, Kamel M, Owen JP, Dick WC. Clinical and laboratory studies of arthritis in leprosy. Br Med J. 1989,298:1423-5.
28. Pernambuco JCA, Cosserrmelli-Messina W. Rheumatic manifestations of leprosy: clinical aspects. J Rheumatol. 1993;20:897-9.
29. Hayata ALS, Gonçalves CR, Souza APTC, Abreu AC, Dulcine M, Gelbert C, et al. Artrite causado pelo "Mycobacterium leprae": causa rara de envolvimento articular na hanseníase? Rev Bras Reumatol. 1999;39:245-7.
30. Lechat M. Bone lesions in Leprosy. Int J Lepr Other Mycobact Dis. 1966;30:125-37.
31. Sales AM, De Sá RP, Jardim MM, Machado AM, Nery JAC. Importância do reconhecimento clínico da hanseníase. J Bras Med. 2004;87:41-50.
32. Gelber RH. Erythema nodosum leprosum associated with azotemic acute glomerulonefritis and recurrent hematuria. Int J Lepr Other Mycobact Dis. 1986;54:125-7.
33. Van Brakel WH, Khawas IB. Nerve damage in leprosy: an epidemiological and clinical study of 396 patients in west Nepal - Part 1. Definitions, methods and frequencies. Lepr Rev. 1994;65:204-21.
34. Loeser JD. Pain and suffering. Clin J Pain. 2000;16(Suppl):S2-6.
35. Nations SP, Katz JS, Lyde C, Barohn RJ. Leprous neuropathy: an America Perspective. Semin Neurol. 1998;18:113-24.
36. Haanpää M, Lockwood DNJ, Hietaharju A. Neuropathic pain. Lepr Rev. 2004;75:7-18.
37. Pearson JMH, Ross WF. Nerve involvement in leprosy - pathology, differential diagnosis and principles of management. Lepr Rev. 1975;46:199-212.
38. Fritsch EP. Field detection of early neuritis in leprosy. Lepr Rev. 1987;58:173-7.
39. Pimentel MIF. Neurites na hanseníase: significado de parâmetros clínicos e epidemiológicos na indução e agravamento das incapacidades físicas nos pacientes multibacilares [tese]. Rio de Janeiro: Universidade Federal do Rio de Janeiro; 1998. p. 109.
40. Saunderson P, Gebre S, Byass P. Reversal reactions in the skin lesions of amfes patients: incidence and risk factors. Lepr Rev. 2000;71:309-17.
41. Moraes MO, Sampaio EP, Nery JA, Saraiva BC, Alvarenga FB, Sarno EN. Sequential erythema nodosum leprosum and reversal reaction with similar lesional cytokine mRNA patterns in a borderline leprosy patient. Br J Dermatol. 2001;144:175-81.
42. Lyra MR. Descrição epidemiológica das reações hansênicas em pacientes multibacilares submetidos a PQT/OMS de 12 doses fixas [tese]. Rio de Janeiro: Instituto de Medicina Tropical da Fundação Oswaldo Cruz; 2004. p. 111.
43. Becx-Bleuminck M, Berhe D. Occurrence of reactions their diagnosis and management in leprosy patients treated with multidrug therapy experience in the leprosy control program of the All Africa leprosy and Rehabilitation Training Centre (ALERT) in Ethiopia. Int J Lepr Other Mycobact Dis. 1992;60:173-84.
44. Lockwood DJ, Vinayakumar S, Stanley JNA, Mcadam KPWJ, Colston MJ. Clinical features and outcome of reversal (Type 1) reactions in Hyderabad. Int J Lepr Other Mycobact Dis. 1993;61:8-18.
45. Gallo MEN, Alvin MFS, Nery JAC, Albuquerque ECA. Estudo comparativo com dois esquemas poliquimioterápico (duração fixa) em hanseníanos multibacilares - Seguimento de 50.32 ± 19.62 e 39.70 ± 19.47 meses. Hansen Int. 1997;22:5-14.
46. Cunha MGS. Episódios reacionais e relação com recidiva em doentes com hanseníase tratados com diferentes esquemas terapêuticos [tese]. Ribeirão Preto: Universidade de São Paulo; 2001. p. 163.
47. Saunderson P, Gebre S, Byass P. Enl reactions in the multibacillary cases of the amfes cohort in central Ethiopia: incidence and risk factors. Lepr Rev. 2000;71:318-24.
48. Carayon A, Languillon J. Les lésions osseuses de la lèpre. Essai pathogénique -Deductions. Presse Med. 1961;69:239-42.
49. Karat S, Karat A, Foster R. Radiological changes in bone of the limbs in leprosy. Lepr Rev. 1968;39:147-69.
50. Datz FL. Erythema nodosum leprosum reaction of leprosy causing the dopuble stripe sign on bone scan: case report. Clin Nucl Med. 1987;12:211-4.
51. Jopling WH, Mcdougall AC. Manual de Hanseníase. Rio de Janeiro: Livraria Atheneu; 1991. p.16.
52. Ishikawa S, Ishikawa A, Yoh K, Tanaka H, Fujiwara M. Osteoporosis in male and female leprosy patients. Calcif Tissue Int. 1999;64:144-7.
53. Illarramendi X, Carregal E, Nery JAC, Sarno EN. Osteopenia associated to steroid therapy in leprosy. Rev Soc Bras Med Trop. 2001;34(Suppl 1):S92.
54. Brasil. Ministério da Saúde. Hanseníase - Atividades de Controle e Manual de Procedimentos; 2001. p. 177.
55. Sampaio EP, Carvalho DS, Nery JAC, Lopes UG, Sarno EN. Thalidomide: an overview of its pharmacological mechanisms of action. Anti-inflammatory and anti-allergy agents. Anti-inflammatory and anti-allergy agents in medicinal chemistry. 2006;5:71-7.
56. Brasil. Ministério da Saúde. Guia para Utilizaç ão de Medicamentos e Imunobiológicos na Área de Hanseníase. Secretaria de Políticas de Saúde. Departamento de Gestão de Políticas Estratégicas. ATDS; 2000. p. 78.
57. Nery JAC, Perisse ARS, Sales AM, Vieira LMM, Souza RV, Sampaio EP, Sarno EN. The use of Pentoxifylline in the treatment of type 2 reactional episodes in leprosy. Indian J Lepr. 2000;72:29-39.
58. Benevenuti PJ. Azatioprina e estados reacionais hansênicos [monografia]. Rio de Janeiro: Universidade Federal do Estado do Rio de Janeiro; 2003. p.101.
59. Jardim MR. Utilização da metilprednisolona na neuropatia da hanseníase [tese]. Rio de Janeiro: Universidade Federal Fluminense; 2000. p. 137.